GSK Shifts Strategy, Axes Adult Vaccine Candidate in $2.1B Affinivax Deal Amid Rising Competition
In a strategic shift, GSK has halted the development of its 24-valent pneumococcal vaccine for adults—a major project from its ...
Tag: GSK
GSK Invests $300M in Next-Generation Lupus Drug from Chimagen Biosciences
Building on its legacy as a leader in lupus treatment, GlaxoSmithKline (GSK) is making a substantial investment in a new ...
